Eli Lilly squares up to Novo Nordisk on obesity market

Eli Lilly has just published phase III data for its obesity candidate, tirzepatide, in a respected US medical journal -- data which shows a significant effect.


Brand new peer-reviewed data on Eli Lilly’s candidate tirzepatide has set the stage for a battle within the obesity market. Novo Nordisk vs Eli Lilly. Tirzepatide vs semaglutide. The US vs Denmark.

US-based industry media Fierce Pharma reports that Eli Lilly’s tirzepatide met both primary and secondary endpoints in its phase III trial Surmount 1, and demonstrated a weight loss of up to 22.5% after 72 weeks of treatment. The data was published in the New England Journal of Medicine.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs